These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 497409)

  • 21. [Inhibition of concanavalin A and phytohemagglutinine P mediated agglutination of L 1210 cells by different azomethines and possible relations to their cytostatic activity (author's transl)].
    Gutsche W; Schulze W; Augsten K; Jungstand W; Wohlrabe K; Wollweber L
    Arch Geschwulstforsch; 1979; 49(4):311-24. PubMed ID: 496569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of leukemia L1210 and P388 by arabinosylcytosine-polysaccharide conjugates.
    Novotný L; Balázová E; Sandula J; Ujházy V; Kéry V
    Int J Cancer; 1991 Jan; 47(2):281-4. PubMed ID: 1988371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
    Chabot GG; Momparler RL
    Cancer Treat Rep; 1984 Dec; 68(12):1483-7. PubMed ID: 6210142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The emergence of drug resistance in tumours: a characteristic which may be exploited therapeutically.
    Tattersall MH
    Br J Cancer; 1973 May; 27(5):406-8. PubMed ID: 4576563
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunosuppressive activity of methotrexate and arabinosyl cytosine in mice bearing L1210 leukaemia.
    Baldini L; Brambilla G; Cavanna M; Parodi S
    Br J Pharmacol; 1968 Nov; 34(3):674P-676P. PubMed ID: 5726804
    [No Abstract]   [Full Text] [Related]  

  • 26. [Experimental basis of combination chemotherapy in the treatment of acute leukemia (author's transl)].
    Hoshino A
    Nihon Ketsueki Gakkai Zasshi; 1974 Oct; 37(5):731-9. PubMed ID: 4480565
    [No Abstract]   [Full Text] [Related]  

  • 27. Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ; Otter GM; Stock CC
    Cancer Treat Rep; 1976 Jan; 60(1):23-7. PubMed ID: 1000516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
    Geroni C; Pesenti E; Tagliabue G; Ballinari D; Mongelli N; Broggini M; Erba E; D'Incalci M; Spreafico F; Grandi M
    Int J Cancer; 1993 Jan; 53(2):308-14. PubMed ID: 8425770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
    Vadlamudi S; Goldin A
    Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
    [No Abstract]   [Full Text] [Related]  

  • 31. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cytogenetic characteristics of the leukemia L1210 strain in the development of drug resistance].
    Goncharova SA; Minenkova EA; Fomina MM; Demidova NS
    Eksp Onkol; 1984; 6(4):38-41. PubMed ID: 6499750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
    Cass CE; Muzik H; Paterson AR
    Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL; Roberts D
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract]   [Full Text] [Related]  

  • 36. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
    Momparler RL; Momparler LF
    Cancer Chemother Pharmacol; 1989; 25(1):51-4. PubMed ID: 2480188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone.
    Grindey GB; Mihich E; Nichol CA
    Cancer Res; 1972 Mar; 32(3):522-6. PubMed ID: 5061306
    [No Abstract]   [Full Text] [Related]  

  • 38. Deoxycytidine and lethal doses of cytarabine in advanced murine leukaemia.
    Buchman VM; Svet-Moldavsky GJ; Lichinitser MR; Mkheidze DM
    Lancet; 1977 May; 1(8020):1061. PubMed ID: 67527
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronochemotherapy: L 1210 leukemia and beyond.
    Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
    Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of 6-N-hydroxylamino-9-beta-D-ribofuranosylpurine in mouse leukemia.
    Burchenal JH; Dollinger M; Butterbaugh J; Stoll D; Giner-Sorolla A
    Biochem Pharmacol; 1967 Mar; 16(3):423-8. PubMed ID: 6034363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.